UBS AM
BBIO icon

UBS AM’s BridgeBio Pharma BBIO Stock Holding History

UBS AM’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.7M Buy
479,758
+76,810
+19% +$5.38M 0.01% 737
2026
Q1 		$29.9M Sell
402,948
-48,068
-11% -$3.48M 0.01% 750
2025
Q4 		$34.5M Sell
451,016
-62,247
-12% -$4.09M 0.01% 693
2025
Q3 		$26.7M Sell
513,263
-191,094
-27% -$9.32M 0.01% 737
2025
Q2 		$30.4M Buy
704,357
+99,411
+16% +$3.62M 0.01% 885
2025
Q1 		$20.9M Sell
604,946
-4,642
-0.8% -$157K 0.01% 950
2024
Q4 		$16.7M Sell
609,588
-50,677
-8% -$1.31M ﹤0.01% 1031
2024
Q3 		$16.8M Sell
660,265
-45,862
-6% -$1.2M ﹤0.01% 1015
2024
Q2 		$17.9M Buy
706,127
+64,232
+10% +$1.76M 0.01% 900
2024
Q1 		$19.8M Sell
641,895
-18,323
-3% -$623K 0.01% 795
2023
Q4 		$26.7M Sell
660,218
-35,415
-5% -$1.06M 0.01% 720
2023
Q3 		$18.3M Sell
695,633
-8,853
-1% -$251K 0.01% 775
2023
Q2 		$11.7M Hold
704,486
– – 0.01% 910
2023
Q1 		$11.7M Buy
704,486
+600,521
+578% +$7M 0.01% 910
2022
Q4 		$792K Sell
103,965
-3,873
-4% -$37.1K ﹤0.01% 1968
2022
Q3 		$1.07M Buy
107,838
+23,150
+27% +$241K ﹤0.01% 1922
2022
Q2 		$769K Buy
84,688
+19,229
+29% +$161K ﹤0.01% 2100
2022
Q1 		$664K Buy
65,459
+498
+0.8% +$5.11K ﹤0.01% 2351
2021
Q4 		$1.08M Sell
64,961
-5,735
-8% -$243K ﹤0.01% 2173
2021
Q3 		$3.31M Buy
70,696
+1,513
+2% +$81.1K ﹤0.01% 1569
2021
Q2 		$4.22M Buy
69,183
+29,742
+75% +$1.7M ﹤0.01% 1456
2021
Q1 		$2.43M Sell
39,441
-125,961
-76% -$8.24M ﹤0.01% 1677
2020
Q4 		$11.8M Sell
165,402
-8,993
-5% -$434K 0.01% 1002
2020
Q3 		$6.54M Sell
174,395
-2,556
-1% -$80.4K ﹤0.01% 1066
2020
Q2 		$5.77M Buy
176,951
+8,005
+5% +$244K ﹤0.01% 1063
2020
Q1 		$4.9M Buy
168,946
+92,212
+120% +$2.86M ﹤0.01% 1054
2019
Q4 		$2.69M Sell
76,734
-217
-0.3% -$6.02K ﹤0.01% 1468
2019
Q3 		$1.65M Buy
76,951
+1,951
+3% +$54K ﹤0.01% 1701
2019
Q2 		$2.02M Buy
+75,000
New +$2.04M ﹤0.01% 1586

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

UBS AM's BBIO Position: Q2 2026 in Review

UBS AM increased its BridgeBio Pharma (BBIO) stake by 19% in Q2 2026, buying an estimated $5.38M and bringing the position to 479,758 shares worth $35.7M. The position accounts for 0.01% of the portfolio, ranked #737.

UBS AM first reported a position in BBIO in Q2 2019 and has held it in 29 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • UBS AM held 479,758 shares of BridgeBio Pharma worth $35.7M as of Q2 2026.
  • UBS AM bought 76,810 BridgeBio Pharma shares in Q2 2026, an estimated $5.38M.
  • BridgeBio Pharma made up 0.01% of UBS AM's portfolio in Q2 2026, its #737 holding.
  • UBS AM first reported a position in BridgeBio Pharma in Q2 2019 and has held it in 29 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.